To include your compound in the COVID-19 Resource Center, submit it here.

Tecentriq combo meets PFS endpoint in Phase III for first-line squamous NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said a combination including anti-PD-L1 mAb Tecentriq atezolizumab (MPDL3280A, RG7446) met the co-primary endpoint of improving progression-free survival (PFS) in the Phase III IMpower131

Read the full 324 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE